PMID- 36986693
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231003
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 3
DP  - 2023 Mar 3
TI  - Layer-by-Layer Hollow Mesoporous Silica Nanoparticles with Tunable Degradation 
      Profile.
LID - 10.3390/pharmaceutics15030832 [doi]
LID - 832
AB  - Silica nanoparticles (SNPs) have shown promise in biomedical applications such as 
      drug delivery and imaging due to their versatile synthetic methods, tunable 
      physicochemical properties, and ability to load both hydrophilic and hydrophobic 
      cargo with high efficiency. To improve the utility of these nanostructures, there 
      is a need to control the degradation profile relative to specific 
      microenvironments. The design of such nanostructures for controlled combination 
      drug delivery would benefit from minimizing degradation and cargo release in 
      circulation while increasing intracellular biodegradation. Herein, we fabricated 
      two types of layer-by-layer hollow mesoporous SNPs (HMSNPs) containing two and 
      three layers with variations in disulfide precursor ratios. These disulfide bonds 
      are redox-sensitive, resulting in a controllable degradation profile relative to 
      the number of disulfide bonds present. Particles were characterized for 
      morphology, size and size distribution, atomic composition, pore structure, and 
      surface area. No difference was observed between in vitro cytotoxicity profiles 
      of the fabricated nanoparticles at 24 h in the concentration range below 100 microg 
      mL(-1). The degradation profiles of particles were evaluated in simulated body 
      fluid in the presence of glutathione. The results demonstrate that the 
      composition and number of layers influence degradation rates, and particles 
      containing a higher number of disulfide bridges were more responsive to enzymatic 
      degradation. These results indicate the potential utility of layer-by-layer 
      HMSNPs for delivery applications where tunable degradation is desired.
FAU - Grunberger, Jason William
AU  - Grunberger JW
AUID- ORCID: 0000-0003-0436-5501
AD  - Utah Center for Nanomedicine, Department of Molecular Pharmaceutics, University 
      of Utah, Salt Lake City, UT 84112, USA.
FAU - Ghandehari, Hamidreza
AU  - Ghandehari H
AD  - Utah Center for Nanomedicine, Department of Molecular Pharmaceutics, University 
      of Utah, Salt Lake City, UT 84112, USA.
AD  - Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 
      84112, USA.
LA  - eng
GR  - R01 ES024681/ES/NIEHS NIH HHS/United States
GR  - 2R01ES024681/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20230303
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10057406
OTO - NOTNLM
OT  - degradation
OT  - drug delivery
OT  - hollow
OT  - layer-by-layer
OT  - mesoporous
OT  - silica nanoparticles
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:01
PMCR- 2023/03/03
CRDT- 2023/03/29 02:02
PHST- 2023/01/24 00:00 [received]
PHST- 2023/02/28 00:00 [revised]
PHST- 2023/03/01 00:00 [accepted]
PHST- 2023/03/30 06:01 [medline]
PHST- 2023/03/29 02:02 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/03 00:00 [pmc-release]
AID - pharmaceutics15030832 [pii]
AID - pharmaceutics-15-00832 [pii]
AID - 10.3390/pharmaceutics15030832 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Mar 3;15(3):832. doi: 10.3390/pharmaceutics15030832.